The Prague Post - Formerra and Evonik Expand Distribution Partnership for Healthcare Grades

EUR -
AED 4.105022
AFN 72.645915
ALL 90.302422
AMD 403.178012
ANG 2.000319
AOA 1025.984857
ARS 1721.891285
AUD 1.592734
AWG 2.011735
AZN 1.919633
BAM 1.952805
BBD 2.251157
BDT 138.486355
BGN 1.95343
BHD 0.42168
BIF 3351.215999
BMD 1.117631
BND 1.431092
BOB 13.250558
BRL 6.034202
BSD 1.117691
BTN 106.329963
BWP 15.418214
BYN 3.287728
BYR 21905.563979
BZD 2.247932
CAD 1.566092
CDF 2587.315315
CHF 0.924254
CLF 0.028021
CLP 1106.410117
CNY 7.454877
CNH 7.452452
COP 3517.519465
CRC 508.815044
CUC 1.117631
CUP 26.824857
CVE 110.09949
CZK 24.350153
DJF 198.624952
DKK 7.47548
DOP 68.230843
DZD 151.032163
EGP 62.880363
ERN 16.764462
ETB 179.9947
FJD 2.517798
FKP 0.835661
GBP 0.837642
GEL 2.898002
GGP 0.835661
GHS 12.992487
GIP 0.835661
GMD 82.704825
GNF 9835.151044
GTQ 8.543819
GYD 234.210775
HKD 8.767647
HNL 30.176291
HRK 7.535846
HTG 146.394156
HUF 367.273048
IDR 20283.881666
ILS 3.446935
IMP 0.835661
INR 106.381298
IQD 1692.093054
IRR 2030743.574809
ISK 136.362508
JEP 0.835661
JMD 177.447836
JOD 0.792458
JPY 176.100058
KES 145.224755
KGS 97.73662
KHR 4554.345592
KMF 492.874661
KPW 1005.86769
KRW 1481.721444
KWD 0.347348
KYD 0.931463
KZT 504.022438
LAK 25155.192731
LBP 100083.839469
LKR 371.380389
LRD 190.276406
LSL 18.620199
LTL 3.300073
LVL 0.676044
LYD 7.169566
MAD 11.006986
MDL 20.085015
MGA 5076.168923
MKD 61.430213
MMK 2346.858728
MNT 4022.347333
MOP 9.032066
MRU 44.914391
MUR 52.65205
MVR 17.267308
MWK 1945.795661
MXN 20.772566
MYR 4.566749
MZN 71.42773
NAD 18.619517
NGN 1500.542687
NIO 41.179084
NOK 10.422354
NPR 170.127542
NZD 1.966946
OMR 0.42977
PAB 1.117676
PEN 3.847443
PGK 5.117298
PHP 71.504341
PKR 309.583597
PLN 4.403521
PYG 6443.117761
QAR 4.07376
RON 5.349434
RSD 117.523359
RUB 90.306002
RWF 1651.858345
SAR 4.185233
SBD 9.013298
SCR 15.57652
SDG 672.257132
SEK 11.121212
SGD 1.431011
SHP 0.83749
SLE 25.649511
SLL 23436.164295
SOS 638.722306
SRD 42.12578
STD 23132.701388
STN 24.587878
SVC 9.780043
SYP 14531.435507
SZL 18.581334
THB 37.753462
TJS 10.310786
TMT 3.911708
TND 3.361278
TOP 2.690986
TRY 55.633008
TTD 7.596281
TWD 36.419903
TZS 2956.136879
UAH 51.028606
UGX 5007.364675
USD 1.117631
UYU 44.821255
UZS 13378.041127
VES 983.279188
VND 28882.374343
VUV 132.765148
WST 3.093369
XAF 655.957
XAG 0.020705
XAU 0.000278210702
XCD 3.020453
XCG 2.014392
XDR 0.790223
XOF 655.957
XPF 119.331742
YER 263.928185
ZAR 18.598019
ZMK 10060.018363
ZMW 22.504282
ZWL 359.876667
SSP 6421.124049
MXV 2.343577
  • RBGPF

    0.3800

    70.53

    +0.54%

  • RYCEF

    0.6000

    16.1

    +3.73%

  • BCC

    -2.3000

    75.44

    -3.05%

  • CMSC

    0.0010

    19.601

    +0.01%

  • NGG

    -0.0900

    81.77

    -0.11%

  • BCE

    -0.1500

    20.25

    -0.74%

  • VOD

    -0.0400

    15.7

    -0.25%

  • RIO

    0.3000

    83.72

    +0.36%

  • JRI

    0.1000

    10.85

    +0.92%

  • GSK

    0.3500

    51.1

    +0.68%

  • RELX

    -0.3600

    40.18

    -0.9%

  • AZN

    0.5700

    172.06

    +0.33%

  • CMSD

    -0.1600

    19.62

    -0.82%

  • BP

    -0.7900

    50.53

    -1.56%

  • BTI

    0.6200

    60.1

    +1.03%

Formerra and Evonik Expand Distribution Partnership for Healthcare Grades
Formerra and Evonik Expand Distribution Partnership for Healthcare Grades

Formerra and Evonik Expand Distribution Partnership for Healthcare Grades

Agreement Expands Access to Evonik's CARE Brand Medical Grades in the U.S. and Canada

Text size:

ROMEOVILLE, ILLINOIS / ACCESS Newswire / February 2, 2026 / Formerra, a leader in performance materials distribution, today announced an expanded distribution agreement that brings Evonik's CARE brand healthcare grades into Formerra's medical portfolio. Covering the United States and Canada, the agreement creates new access points for high-performance polyamides used in essential healthcare applications.

This expansion kicks off at MD&M West 2026 this week, and underscores both companies' commitment to supporting the healthcare market with high-performance materials, responsive service, and continuity of supply. It also builds on the companies' two-year partnership, which introduced Evonik's VESTAMID® and TROGAMID® families to Formerra's engineered materials lineup.

With this expansion, Formerra will support Evonik healthcare grades designed for fluid handling, drug delivery, diagnostic systems, surgical instrument parts, medical device housings, components that see short-term body contact (

Key medical grade materials include:

  • VESTAMID® Care ML PA12

  • VESTAMID® Care ME PEBA elastomer

  • TROGAMID® Care MX microcrystalline PA

"Our healthcare customers rely on stable supply, world-class regulatory support, and materials that perform under demanding conditions," said Steve Harmon, Director, Key Accounts, Formerra. "Evonik's healthcare grades bring the combination of durability, processing consistency, and documentation support that medical manufacturers require. This expansion lets us strengthen the technical resources and materials pipeline available to teams developing next-generation devices."

"Formerra's ability to serve the whole supply chain in the medical space, from design companies to compounders to medical device OEMs, with technical rigor and exceptional logistics and with already-proven successful demonstration in the industrial space, made this expansion with CARE brand Polyamide 12 products a natural step," said Basker Lalgudi, Business Manager, Global Medical Devices, Evonik. "Their healthcare expertise and focus help customers select and implement our materials with confidence across a range of critical applications."

By adding Evonik's healthcare CARE brand materials, Formerra will offer customers a proven set of polyamide solutions that support regulatory pathways, design requirements, and long-term reliability. Formerra's team will provide material selection guidance, processing support, and regional supply chain readiness to help OEMs and molders accelerate development cycles.

Formerra will exhibit at MD&M West in Booth 2266 in Anaheim, California, Feb. 3-5, 2026.

Key Details:

  • Formerra will distribute Evonik's CARE brand healthcare grades across the U.S. and Canada.

  • Materials include healthcare grades within the VESTAMID® L, VESTAMID® E, and TROGAMID® CX families, plus designated sustainable options.

  • The agreement strengthens Formerra's medical portfolio and expands its support for fluid management, diagnostics, wearables, and device housings.

  • Formerra will provide application guidance, regulatory documentation support, and supply chain continuity for medical customers.

About Formerra

Formerra is a preeminent distributor of engineered materials, connecting the world's leading polymer producers with thousands of OEMs and brand owners across healthcare, consumer, industrial, and mobility markets. Powered by technical and commercial expertise, it brings a distinctive combination of portfolio depth, supply chain strength, industry knowledge, service, leading e-commerce capabilities, and ingenuity. The experienced Formerra team helps customers across multiple industries to design, select, process, and develop products in new and better ways, driving improved performance, productivity, reliability, and sustainability. To learn more, visit www.formerra.com.

About Evonik

Evonik goes beyond the boundaries of chemistry with its combination of innovative strength and leading technological expertise. The global chemical company, headquartered in Essen, Germany, is active in more than 100 countries and generated sales of €15.2 billion and earnings (adjusted EBITDA) of €2.1 billion in 2024. The common motivation of the approximately 32,000 employees: to provide customers with a decisive competitive advantage with tailor-made products and solutions as a superforce for industry, thereby improving people's lives. In all markets. Every day. To learn more, visit www.evonik.com.

Media Contact
Jackie Morris
Marketing Communications Manager, Formerra
[email protected]
+1 630-972-3144

SOURCE: Formerra



View the original press release on ACCESS Newswire

H.Dolezal--TPP